%PDF-1.3
%
1 0 obj
<<
/OpenAction <<
/Type /Action
/S /GoTo
/D [2 0 R /XYZ null null null]
>>
/Type /Catalog
/Outlines 3 0 R
/Metadata 4 0 R
/Pages 5 0 R
/PageMode /UseNone
/JT 6 0 R
/AcroForm 7 0 R
>>
endobj
8 0 obj
<<
/ModDate (D:20010525120000-04'00')
/Author (Backhus, Stephen P;Brier, Dan;Kirby, Carolyn;Lew, William;Richardson, Allan;Sloan, Karen;Wade, Richard)
/Producer (Etymon PJ 1.10, Copyright \(C\) 1998-2000 Etymon Systems, Inc. . )
/Title (DOD and VA Pharmacy: Progress and Remaining Challenges in Jointly Buying and Mailing Out Drugs)
/CreationDate (D:20010525120000-04'00')
/Keywords (chemical synthesis;health services;medical personnel;pharmacies;drug abuse;chemotherapy;chemistry;drug addiction;alkynes;anticonvulsants;organic chemistry;enzyme inhibitors;anti-infective agents;antidepressants;congress;law)
/Subject (In fiscal year 2000, the Department of Veterans Affairs \(VA\) and the Department of Defense \(DOD\) together spent about $3.2 billion on prescription drugs for beneficiaries. Reflecting national trends, VA and DOD drug expenditures have risen significantly, consuming an increasing percentage of their health care budgets. Newly legislated initiatives are projected to further boost DODs annual drug costs by $800 million in fiscal year 2002. To help control these expenditures, VA and DOD have separately and, more recently, jointly contracted for pharmaceuticals to obtain large discounts from drug manufacturers.1 Considerable leverage can be exerted when the departments commit to buy increased volumes of a particular drug when there are generic drugs or brand name drugs2 that are interchangeable in efficacy, safety, and outcomes. The departments ability to commit to jointly buy more of a particular drug depends largely on their ability to influence provider prescribing practices through the use of formularies.3)
/Filename (/pdf/TRECMS/AD1166924.pdf)
>>
endobj
2 0 obj
<<
/Type /Page
/Rotate 0
/CropBox [0 0 612 792]
/MediaBox [0 0 612 792]
/Contents [9 0 R 10 0 R 11 0 R 12 0 R 13 0 R 14 0 R 15 0 R 16 0 R]
/Resources 17 0 R
/Thumb 18 0 R
/Parent 5 0 R
>>
endobj
3 0 obj
<<
/Type /Outlines
/First 19 0 R
/Last 20 0 R
/Count 26
>>
endobj
4 0 obj
<<
/Length 1544
/Type /Metadata
/Subtype /XML
>>
stream
Etymon PJ 1.10, Copyright (C) 1998-2000 Etymon Systems, Inc. . Stephen Backhus, Caroloyn KirbyGAO-01-588 DOD and VA Pharmacy: Progress and Remaining Challenges in Jointly Buying and Mailing Out Drugs
endstream
endobj
5 0 obj
<<
/Kids [2 0 R 21 0 R 22 0 R 23 0 R 24 0 R 25 0 R 26 0 R 27 0 R 28 0 R 29 0 R
30 0 R 31 0 R 32 0 R 33 0 R 34 0 R 35 0 R 36 0 R 37 0 R 38 0 R 39 0 R
40 0 R 41 0 R 42 0 R 43 0 R 44 0 R 45 0 R 46 0 R 47 0 R 48 0 R 49 0 R
50 0 R 51 0 R 52 0 R 53 0 R 54 0 R 55 0 R 56 0 R 57 0 R 58 0 R 59 0 R
60 0 R 61 0 R 62 0 R 63 0 R 64 0 R 65 0 R 66 0 R 67 0 R 68 0 R 69 0 R
70 0 R 71 0 R 72 0 R 73 0 R 74 0 R 75 0 R 76 0 R 77 0 R]
/Count 58
/Type /Pages
>>
endobj
6 0 obj
<<
/A [78 0 R]
/Cn [79 0 R]
/V 1.1
>>
endobj
7 0 obj
<<
>>
endobj
9 0 obj
<<
/Length 4832
/Filter /FlateDecode
>>
stream
HWn}߯ HKl~`r}Ωa꺜JݫVQ*=(Z}X}Q+vj墊OΪU(z}7u__}{o>ɚ<3nJOΧn ]}Y\O@dzvFNLZ%~ÓzW/zsޫwOOۇWakvj$XZ)]1UͿ6U6T}T6;a ;r__Stzѓ3~`$]tbey}- ?;buuǏ-E̡EP~3Dlˢۦ(!H"lPq;-/I\4%sP֦76_Ѧv[rn79Qȶro_T?\*Z]@˺.7\wcGP?KBÇ9~ViHawU/~ﷇ#O]E4A_շ\SYC7pS\ߪ?
zbcO%I}(g ߊd5"/a-.6f
:܍/˒8[ (E%t] ҔWnVmdm~#bywb\S38E*8_[b1-0Օ0/˔w ֮
qLe?
:6v7e<&s\v0Iq!m~2rw]S9'V}Q7Ȱ1{[RD$#r۾d%l9cmٜqCyannQ:!Isvi$f7yQ;ΣjI&<+Fm;ϏW MDJ8ܻ휻pe
ok(_x4rXc2n})
F]غ~FQHBGP神e
- ˈzj}
Wb`9`{`EdF%FZ FؕxjFK6WO؛УpSP &,v(PЁIZVhOxij \HbòRc;3
_
J_gL"My;=6Z~lH%I:QpH墮g;yeђ%Q>~/g3Дݴ#oO+U^g>џz8z3_轲)H"b3f 'C @tha'@t-k1FlypC!=$oi~nͬOS4 @%)],,tl`&6 Cev*853pGc${BՊ 0V%*l"3 _[) l,)\goFLU+H+&H֠NS,y .# &ieɤ3 &Eg+@Y!#ɂ 'j l)\Ӆ"hh#{